Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets

03. Biogen Inc. (NASDAQ:BIIB)

Upside Potential: 43%

Biogen Inc. (NASDAQ:BIIB) is an American firm that makes and sells treatments for nervous system disorders. The firm has beaten analyst EPS estimates in all four of its latest quarters. On September 5, Morgan Stanley increased its price target for Biogen Inc. (NASDAQ:BIIB) from $363.00 to $381.00 while maintaining an “Overweight” rating for the company’s shares. Despite the stock’s marginal decrease of 0.3% in share price on September 5, the new target reflects Morgan Stanley’s positive outlook on Biogen Inc. (NASDAQ:BIIB). This adjustment underscores Morgan Stanley’s belief in the growth potential of Biogen. It suggests that Biogen Inc. (NASDAQ:BIIB) may not only justify its existing “Overweight” rating but also potentially reach the newly established target of $381.00, according to Morgan Stanley’s analysis.